Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Technology appraisal guidance
Reference number: TA870
Published:
In December 2021 we informed you that further evidence was required to develop recommendations for this technology. Work to progress this appraisal is continuing and we will provide a further update by 31 May 2022.